Background: The synthetic biology technology which enhances the specificity and efficacy of treatment is a novel try in biomedical therapy during recent years. A high frequency of somatic mutations was shown in the human telomerase reverse transcriptase (hTERT) promoter in bladder cancer, indicating that a mutational hTERT promoter might be a tumor-specific element for bladder cancer therapy. In our study, we aimed to construct a synthetic combination module driven by a super artificial hTERT promoter and to investigate its influence on the malignant phenotypes of bladder cancer.
Methods: The dual luciferase assay system was used to verify the driven efficiency and tumor-specificity of the artificial hTERT promoter and to confirm the relationship between ETS-1 and the driven efficiency of the artificial hTERT promoter. CCK-8 assay and MTT assay were used to test the effects of the Bax-Anti Bcl2 combination module driven by the artificial hTERT promoter on cell proliferation. Simultaneously, the cell apoptosis was detected by the caspase 3ELISA assay and the flow cytometry analysis after transfection. The results of CCK-8 assay and MTT assay were analyzed by ANOVA. The independent samples t-test was used to analyze other data.
Results: We demonstrated that the artificial hTERT promoter had a higher driven efficiency which might be regulated by transcription factor ETS-1 in bladder cancer cells, compared with wild-type hTERT promoter. Meanwhile, the artificial hTERT promoter showed a strong tumor-specific effect. The cell proliferation inhibition and apoptosis induction were observed in artificial hTERT promoter- Bax-Anti Bcl2 combination module -transfected bladder cancer 5637 and T24 cells, but not in the module -transfected normal human fibroblasts.
Conclusion: This module offers us a useful synthetic biology platform to inhibit the malignant phenotypes of bladder cancer in a more specific and effective way.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705585 | PMC |
| http://dx.doi.org/10.1186/s13046-015-0279-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tissue factor signalling modifies the expression and regulation of G1/S checkpoint regulators: Implications during injury and prolonged inflammation.
Mol Med Rep
February 2025
Biomedical Section, Hull-York Medical School, University of Hull, Hull, HU6 7RX, UK.
Tissue factor (TF) possesses additional physiological functions beyond initiating the coagulation cascade. Cellular signals initiated by cellular TF or on contact with TF‑containing microvesicles, contribute to wound healing through regulating a number of cellular properties and functions. TF regulates the cell cycle checkpoints, however the underlying signalling mechanisms have not been determined.
View Article and Find Full Text PDFTERTmonitor Efficacy and Performance in Detecting Mutations by Droplet Digital PCR.
Genes (Basel)
October 2024
U-Monitor Lda, 4200-135 Porto, Portugal.
Background: The screening of TERT promoter () mutations is essential in cancer research and diagnostics, due to its prevalence in tumours associated with low self-renewal rates. TERTmonitor is a diagnosis kit primarily designed for real-time qPCR qualitative detection of -124C>T and -146C>T mutations, which are highly prevalent in several malignancies, particularly in bladder carcinoma.
Objective: This study aims to investigate TERTmonitor performance in droplet digital PCR (ddPCR) in urine samples from bladder cancer patients.
Diffuse pediatric high-grade glioma of methylation-based RTK2A and RTK2B subclasses present distinct radiological and histomolecular features including Gliomatosis cerebri phenotype.
Acta Neuropathol Commun
November 2024
Department of Neuropathology, GHU Paris-Psychiatrie et Neurosciences, Sainte-Anne Hospital, 1, Rue Cabanis, 75014, Paris, France.
Diffuse pediatric-type high-grade gliomas (pedHGG), H3- and IDH-wildtype, encompass three main DNA-methylation-based subtypes: pedHGG-MYCN, pedHGG-RTK1A/B/C, and pedHGG-RTK2A/B. Since their first description in 2017 tumors of pedHGG-RTK2A/B have not been comprehensively characterized and clinical correlates remain elusive. In a recent series of pedHGG with a Gliomatosis cerebri (GC) growth pattern, an increased incidence of pedHGG-RTK2A/B (n = 18) was observed.
View Article and Find Full Text PDFAssociation between human telomerase reverse transcriptase (hTERT) MNS16A polymorphism and risk of breast cancer.
Mol Biol Rep
October 2024
Department of Biology, School of Science, Shiraz University, Shiraz, 71467-13565, Iran.
Article Synopsis
- - The study investigates the role of the MNS16A genetic polymorphism in the hTERT gene and its possible link to breast cancer risk, given that telomerase activity is usually low in normal tissues but increased in tumors.
- - Researchers analyzed 711 samples, including 362 breast cancer patients and 349 healthy individuals, using DNA genotyping to assess the presence of short and long alleles related to the MNS16A polymorphism.
- - Results showed no significant association between the MNS16A polymorphism and breast cancer risk across various genetic models, indicating the need for further research with larger populations to explore this relationship.
Obesity-Senescence-Breast Cancer: Clinical Presentation of a Common Unfortunate Cycle.
Adv Exp Med Biol
September 2024
Faculty of Medicine, Department of General Surgery, Gazi University, Besevler, Ankara, Turkey.
Article Synopsis
- There is limited research on how obesity, cell aging, and telomere shortening are interrelated, but it is established that telomere shortening contributes significantly to aging and age-related illnesses.* -
- Telomerase activity, which helps maintain telomere length, is absent in normal breast tissue but is crucial for the survival and growth of breast cancer cells, particularly in obese patients with hormone-dependent cancers.* -
- The review discusses how elevated leptin levels in obesity can enhance breast cancer cell growth by affecting telomerase activity and explores potential drug therapies targeting telomerase to treat ERα+ postmenopausal breast cancers.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!